Abstract
Neurofibromatosis 1 (NF1) is a comparatively common autosomal dominant disorder. However, relatively few studies have assessed lifetime risk; and information about the effect of NF1 on mortality remains uncertain. NF1 patients were identified using The North West regional family Genetic Register, which covers the 4.1 million people living in North West England, including the regions of Greater Manchester, Cheshire and Cumbria. Data relating to tumours and malignancies were obtained from The North West Cancer Intelligence Service. Death data for the general North West population were obtained from the Office of National Statistics. We identified 1186 individuals with NF1, of whom 1023 lived within the strict regional boundaries (constituting a region of North West England bound by The Pennines to the east and Irish Sea to the west, but excluding the conurbation of Liverpool (Merseyside) and the Wirral peninsula) and 131 had died. MPNST and glioma were found to be the two most common causes of reduced life expectancy among NF1 patients. In Kaplan–Meier analyses the median survival for NF1 patients was shown to be 71.5 years, with women living ∼7.4 years longer than men. On average both men and women lived ∼8 years less than their counterparts in the general population. Reduction in life expectancy for NF1 patients was found to be much lower (8 years) than the previously estimated 15-year decrease. Limitations relating to the underreporting of NF1 on death certificates were once again highlighted and should be considered in future investigations.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Sorensen SA, Mulvihill JJ, Nielsen A : Long term follow up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl J Med 1986; 314: 1010–1015.
Zöller M, Rembeck B, Akesson HO, Angervall L : Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol 1995; 75: 136–140.
Rasmussen SA, Yang Q, Friedman JM : Mortality in neurofibromatosis 1: an analysis using US death certificates. Am J Hum Genet 2001; 68: 1110–1118.
Evans DGR, Baser ME, McGaughran J, Sharif S, Donnelly B, Moran A : Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39: 311–314.
McGaughran JM, Harris DI, Donnai D et al: A clinical study of type 1 neurofibromatosis in North West England. J Med Genet 1999; 36: 192–196.
Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R : NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 1990; 113: 39–52.
Office of National Statistics: Death rates 2008. http://www.statistics.gov.uk/downloads/theme_health/DR2008/DR_08.pdf.
Samuelsson B, Samuelsson S : Neurofibromatosis in Gothenburg, Sweden. I. Background, study design and epidemiology. Neurofibromatosis 1989; 2: 6–22.
Sharif S, Moran A, Huson SM et al: Women with neurofibromatosis 1 (NF1) are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007; 44: 481–484.
Huson SM, Compston DA, Clark P, Harper PS : A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989; 26: 704–711.
Lammert M, Friedman JM, Kluwe L, Mautner VF : Prevalence of neurofibromatosis 1 in German children at elementary school enrolment. Arch Dermatol 2005; 141: 71–74.
Evans DG, Howard E, Giblin C et al: Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service. Am J Med Genet 2010; 152A: 327–332.
Imaizumi Y : Mortality of neurofibromatosis in Japan, 1968–1992. J Dermatol 1995; 22: 191–195.
Walker L, Thompson D, Easton D et al: A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006; 95: 233–238.
Evans DGR, Birch JM, Ramsden RT, Moffat D, Baser ME : Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour-prone syndromes. J Med Genet 2006; 43: 289–294.
Sharif S, Ferner R, Birch J, Gattamaneni R, Gillespie J, Evans DGR : Second primary tumours in neurofibromatosis 1 (NF1) patients treated for optic glioma: substantial risks post radiotherapy. J Clin Oncol 2006; 24: 2570–2575.
Singhal S, Kerr B, Birch J, Lashford L, Evans DGR : Clinical characteristics of symptomatic sporadic and NF1 related optic gliomata: implications for management. Archives Dis Child 2002; 87: 65–70.
King A, Listernick R, Charrow J, Piersall L, Gutmann DH : Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 2003; 122A: 95–99.
Hartley AL, Birch JM, Kelsey AM, Harris M, Jones PH : Sarcomas in three generations of a family with neurofibromatosis. Cancer Genet Cytogenet 1990; 45: 245–248.
Acknowledgements
We acknowledge the support of the NIHR Biomedical Research Centre at Central Manchester Foundation Trust.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Evans, D., O'Hara, C., Wilding, A. et al. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet 19, 1187–1191 (2011). https://doi.org/10.1038/ejhg.2011.113
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2011.113
Keywords
This article is cited by
-
When Neurofibromatosis Meets Diabetes: A Long-Term Follow-up in a Pediatric Case Report
SN Comprehensive Clinical Medicine (2023)
-
Establishment of in-hospital clinical network for patients with neurofibromatosis type 1 in Nagoya University Hospital
Scientific Reports (2021)
-
Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study
Genetics in Medicine (2020)
-
Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors
Scientific Reports (2020)
-
Biallelic NF1 inactivation in high grade serous ovarian cancers from patients with neurofibromatosis type 1
Familial Cancer (2020)
